Nadia Harbeck, Prof. Dr.
LMU Clinics, Breast Centre and CCC · Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital · Ludwigs-Maximilians-University Munich, Breast Cancer Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nadia Harbeck, Prof. Dr. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:02 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07242352 · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCWomen's Cancer Study Group GmbH · recruiting · Breast Cancer, HR+/HER2- Breast Cancer
- Ph3NCT07178730 · NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerWomen's Cancer Study Group GmbH · not yet recruiting · Breast Cancer, Triple-negative Breast Cancer
- Ph3NCT06081244 · NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Women's Cancer Study Group GmbH · recruiting · Triple Negative Breast Cancer
- N/ANCT05792150 · PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSWomen's Cancer Study Group GmbH · recruiting · Female Breast Cancer · principal investigator
- Ph2NCT05704829 · NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerWomen's Cancer Study Group GmbH · recruiting · HER2-positive Early Breast Cancer · principal investigator
- Ph3NCT04055493 · Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCWomen's Cancer Study Group GmbH · active not recruiting · Breast Cancer Female · principal investigator
- N/ANCT02269813 · PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph3NCT02214381 · A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low ResponseWomen's Cancer Study Group GmbH · completed · Early Primary Breast Cancer · principal investigator
- Ph2NCT01817452 · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT ProtocolWomen's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph2NCT01815242 · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast CancerWomen's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph2/Ph3NCT01781338 · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerWomen's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph2/Ph3NCT01779206 · ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerWomen's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph2NCT01745965 · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.Women's Cancer Study Group GmbH · completed · Breast Cancer · principal investigator
- Ph2NCT01690325 · Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)Women's Cancer Study Group GmbH · terminated · Breast Cancer · principal investigator
- Ph3NCT01049425 · Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast CancerWomen's Cancer Study Group GmbH · completed · Primary Breast Cancer, Her2 Non-overexpressing · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.